Robert A Seder

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine
    Robert A Seder
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA
    Science 341:1359-65. 2013
  2. doi request reprint T-cell quality in memory and protection: implications for vaccine design
    Robert A Seder
    Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 8:247-58. 2008
  3. ncbi request reprint Similarities and differences in CD4+ and CD8+ effector and memory T cell generation
    Robert A Seder
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    Nat Immunol 4:835-42. 2003
  4. ncbi request reprint Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses
    Ulrike Wille-Reece
    Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:7676-83. 2005
  5. pmc IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform
    Patricia A Darrah
    Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 207:1421-33. 2010
  6. pmc Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
    Ulrike Wille-Reece
    Cellular Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 203:1249-58. 2006
  7. pmc HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates
    Ulrike Wille-Reece
    Cellular Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 102:15190-4. 2005
  8. pmc Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability
    Susana Mendez
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Infect Immun 71:5121-9. 2003
  9. ncbi request reprint Optimization of DNA vaccination against cutaneous leishmaniasis
    Susana Mendez
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 126, Building 4, Center Dr MSC 0425, Bethesda, MD 20892 0425, USA
    Vaccine 20:3702-8. 2002
  10. pmc Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice
    Javeed A Shah
    VRC, NIAID, 40 Convent Dr, Room 40 3512, NIH, Bethesda, MD 20892, USA
    J Exp Med 198:281-91. 2003

Detail Information

Publications38

  1. doi request reprint Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine
    Robert A Seder
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA
    Science 341:1359-65. 2013
    ..These data indicate that there is a dose-dependent immunological threshold for establishing high-level protection against malaria that can be achieved with IV administration of a vaccine that is safe and meets regulatory standards...
  2. doi request reprint T-cell quality in memory and protection: implications for vaccine design
    Robert A Seder
    Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, Maryland 20892, USA
    Nat Rev Immunol 8:247-58. 2008
    ....
  3. ncbi request reprint Similarities and differences in CD4+ and CD8+ effector and memory T cell generation
    Robert A Seder
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 3005, USA
    Nat Immunol 4:835-42. 2003
    ..This review compares and contrasts how naive CD4+ and CD8+ T cells make the transition to effector and/or memory cells and discusses the implications of these findings for vaccine development...
  4. ncbi request reprint Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses
    Ulrike Wille-Reece
    Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:7676-83. 2005
    ..Overall, these data provide evidence that TLR7/8 agonists can be effective vaccine adjuvants for eliciting strong primary immune responses with a viral protein in vivo, provided vaccine delivery is optimized...
  5. pmc IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform
    Patricia A Darrah
    Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 207:1421-33. 2010
    ..Overall, we delineate distinct mechanisms by which vaccines elicit protective Th1 responses and underscore the importance of multifunctional CD4(+) T cells...
  6. pmc Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates
    Ulrike Wille-Reece
    Cellular Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    J Exp Med 203:1249-58. 2006
    ..These data provide insights for designing prime-boost immunization regimens to optimize Th1 and CD8+ T cell responses...
  7. pmc HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates
    Ulrike Wille-Reece
    Cellular Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 102:15190-4. 2005
    ..This type of vaccine formulation should have utility in preventive or therapeutic vaccines in which humoral and cellular immunity is required...
  8. pmc Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability
    Susana Mendez
    Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Infect Immun 71:5121-9. 2003
    ..Our results suggest that immune modulation using CpG ODNs might be a practical approach to improving the safety of a highly effective live vaccine that has already been widely applied...
  9. ncbi request reprint Optimization of DNA vaccination against cutaneous leishmaniasis
    Susana Mendez
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Room 126, Building 4, Center Dr MSC 0425, Bethesda, MD 20892 0425, USA
    Vaccine 20:3702-8. 2002
    ..These results establish intradermal vaccination using DNA encoding multiple Leishmania antigens as a way to optimize priming of CD4+ and CD8+ T cells necessary for potent and durable protection against cutaneous leishmaniasis...
  10. pmc Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice
    Javeed A Shah
    VRC, NIAID, 40 Convent Dr, Room 40 3512, NIH, Bethesda, MD 20892, USA
    J Exp Med 198:281-91. 2003
    ..Therefore, the combination of LACK antigen and CpG ODN adjuvant leads to the presence of CD11c+ DCs in the draining LN that are capable of vaccinating naive mice in the absence of further antigen or adjuvant...
  11. ncbi request reprint Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses
    Karin Lore
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3022, USA
    J Immunol 171:4320-8. 2003
    ....
  12. doi request reprint CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling
    Ross W B Lindsay
    Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 185:1513-21. 2010
    ..Taken together, these data demonstrate a critical role for CD11c(+) DCs for CD8 responses but striking redundancy for innate cytokines and signaling by TLR and nucleotide-binding oligomerization domain-like receptor pathways...
  13. doi request reprint Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity
    Kylie M Quinn
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892
    J Immunol 191:5085-96. 2013
    ..These data illustrate how combining adjuvants, such as poly I:C and ISCOMs, that modulate Ag processing and have potent innate activity, can enhance the magnitude, quality, and phenotype of T cell immunity. ..
  14. ncbi request reprint Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses
    Marc Tritel
    Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    J Immunol 171:2538-47. 2003
    ..Together, these data suggest a new immunization approach for elicitation of long term humoral and cellular immune responses...
  15. ncbi request reprint Immunological and pathological evaluation of rhesus macaques infected with Leishmania major
    Brenda L Freidag
    Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Exp Parasitol 103:160-8. 2003
    ..Finally, an ELIspot assay determined that the magnitude and kinetics of responses differed between previously infected and naïve monkeys...
  16. ncbi request reprint Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo
    Chang You Wu
    Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3005, USA
    Nat Immunol 3:852-8. 2002
    ..These data suggest that a linear differentiation pathway, as defined by the transition from IFN-gamma-producing to resting memory cells, is relatively limited in vivo and support a revised model for T(H)1 memory differentiation...
  17. pmc Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization
    Kylie M Quinn
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 190:2720-35. 2013
    ..Collectively, these data provide the immunologic basis for using specific rAd vectors alone or as part of prime-boost regimens to induce CD8(+) T cells for rapid effector function or robust long-term memory, respectively...
  18. pmc CD4 T follicular helper cell dynamics during SIV infection
    Constantinos Petrovas
    Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA
    J Clin Invest 122:3281-94. 2012
    ..Therefore, chronic SIV does not disturb the ability of TFH cells to help B cell maturation and production of SIV-specific immunoglobulins...
  19. pmc Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity
    Matthew J Johnson
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 188:6109-18. 2012
    ..Taken together, our results demonstrate that rAd-induced IFN-α production has multiple effects on T cell immunogenicity, the understanding of which should be considered in the design of rAd vaccine vectors...
  20. ncbi request reprint IFN-gamma mediates the death of Th1 cells in a paracrine manner
    Kathryn E Foulds
    Cellular Immunology Section, Human Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 180:842-9. 2008
    ..Collectively, these data show the multiple mechanisms by which Th1 effector cells are efficiently eliminated in vivo...
  21. pmc Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets
    Kathrin Kastenmüller
    Vaccine Research Center and Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA
    J Clin Invest 121:1782-96. 2011
    ....
  22. pmc SIV infection of rhesus macaques results in dysfunctional T- and B-cell responses to neo and recall Leishmania major vaccination
    Nichole R Klatt
    Program in Barrier Immunity and Repair, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 118:5803-12. 2011
    ....
  23. ncbi request reprint Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major
    Patricia A Darrah
    Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases NIAID, National Institutes of Health NIH, 40 Convent Drive, Bethesda, Maryland 20892, USA
    Nat Med 13:843-50. 2007
    ....
  24. pmc Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection
    Elizabeth G Rhee
    Cellular Immunology Section, Vaccine Research Center, Bethesda, MD 20892, USA
    J Exp Med 195:1565-73. 2002
    ....
  25. pmc Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates
    Kavita Tewari
    Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Vaccine 28:7256-66. 2010
    ..Taken together, these data showing that poly(I:C) is an effective adjuvant for inducing potent antibody and Th1 immunity with CSP based vaccines offers a potential alternative to the existing protein based pre-erythrocytic vaccines...
  26. ncbi request reprint IL-10 is required for optimal CD8 T cell memory following Listeria monocytogenes infection
    Kathryn E Foulds
    Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Drive, Bethesda, MD 20892, USA
    J Immunol 177:2565-74. 2006
    ..Overall, these data show that IL-10 plays an unexpected role in promoting and/or sustaining CD8 T cell memory following Listeria monocytogenes infection...
  27. pmc Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A
    Joanna R Kirman
    Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, and Food and Drug Administration, Bethesda, Maryland 20892, USA
    Infect Immun 71:575-9. 2003
    ..pSINCP-85A was highly immunogenic in mice and gave enhanced long-term protection against M. tuberculosis compared with the conventional vector...
  28. pmc TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity
    Teresa R Johnson
    Vaccine Research Center, Viral Pathogenesis Laboratory, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892 3017, USA
    Vaccine 27:3045-52. 2009
    ..Furthermore, these data underscore that amplification of anti-viral immune responses may result in immunopathology rather than immune-mediated protection...
  29. ncbi request reprint Th1 memory: implications for vaccine development
    Kathryn E Foulds
    Cellular Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Immunol Rev 211:58-66. 2006
    ..In conclusion, we discuss how this current understanding of Th1 differentiation will inform vaccine design and better define immune correlates of protection...
  30. pmc Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I·C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice
    Kathrin Kastenmüller
    Vaccine Research Center and Cellular Immunology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Infect Immun 81:789-800. 2013
    ..Overall, these data suggest that full-length CS proteins and poly(I · C)LC or GLA-SE offer a simple vaccine formulation to be used alone or in combination with other vaccines for preventing malaria infection...
  31. pmc Convergent recombination shapes the clonotypic landscape of the naive T-cell repertoire
    Maire F Quigley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:19414-9. 2010
    ..These findings provide a framework for understanding the early mobilization of public CD8(+) T-cell clonotypes, which can exert profound biological effects during acute infectious processes...
  32. pmc Genetic immunization in the lung induces potent local and systemic immune responses
    Kaimei Song
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:22213-8. 2010
    ..Thus, genetic immunization in the lung offers a powerful platform approach to generating protective immune responses against respiratory pathogens...
  33. doi request reprint Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV
    Mario Roederer
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA
    Nature 505:502-8. 2014
    ..These analyses provide insight into the limited efficacy seen in HIV vaccine trials. ..
  34. ncbi request reprint CpG oligodeoxynucleotides as vaccine adjuvants in primates
    Daniela Verthelyi
    Divisions of Viral Products and Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research Food and Drug Administration, Bethesda, MD 20892, USA
    J Immunol 168:1659-63. 2002
    ..These findings indicate that rhesus macaques provide a useful model for studying the in vivo activity of human CpG motifs, and that ODN expressing these motifs act as strong immune adjuvants...
  35. pmc Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs
    Barbara Flynn
    Division of Therapeutic Proteins, Center for Drug Evaluation and Review, Food and Drug Administration, Washington, D C, USA
    Infect Immun 73:4948-54. 2005
    ..major treatment. Together, these findings support the development of clinical studies to assess the use of CpG ODN types D/A as immunoprotective and therapeutic agents...
  36. ncbi request reprint The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses
    Dan H Barouch
    Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Boston, MA, USA
    Immunol Rev 202:266-74. 2004
    ..Here, we review recent advances in our understanding of cytokine biology, T-lymphocyte differentiation, and potential applications of plasmid cytokines in the rational design of improved vaccines...
  37. ncbi request reprint Memory may not need reminding
    Robert A Seder
    Nat Med 10:1045-7. 2004
  38. ncbi request reprint DNA vaccination: the answer to stable, protective T-cell memory?
    Joanna R Kirman
    Malaghan Institute of Medical Research, PO Box 7060, Wellington South, New Zealand
    Curr Opin Immunol 15:471-6. 2003
    ..Utilising this knowledge could contribute to the refinement of DNA vaccine technology to induce more robust and longer-lasting protective T-cell based immunity...